Literature DB >> 2124370

[Acute Chagas' disease: transmission routes, clinical aspects and response to specific therapy in diagnosed cases in an urban center].

M A Shikanai-Yasuda1, M H Lopes, J E Tolezano, E Umezawa, V Amato Neto, A C Barreto, Y Higaki, A A Moreira, G Funayama, A A Barone.   

Abstract

The authors report clinical features and therapeutic response of 24 outpatients with acute Chagas' disease, and 3 in the initial chronic phase, referred to the Clinic for Infectious and Parasitic Diseases of the FMUSP "Clínicas" Hospital between 1974 and 1987. The following transmission routes were involved: triatominae in 7 cases, blood transfusion in 9, kidney transplantation and/or blood transfusion in 4, accidental in 1, oral route in 3, probably breast feeding in 1, congenital or breast feeding in 1, and congenital or blood transfusion in 1. Six patients infected by triatominac acquired the disease between 1974 and 1980 and one in 1987. The blood transfusion infected patients acquired the disease in Greater São Paulo, seven of whom after 1983. The acute phase Chagas' disease was oligosymptomatic in 4 patients: three of such patients being immunocompromised by drugs or other diseases. Another two adult immunocompromised patients developed myocarditis and congestive heart failure. Clinical features were severe in 5 from 6 children under two years, irrespective of the transmission route. Evaluation of the acute phase patients treated with benznidazol (4-10 mg/kg/day) showed: therapeutic failure in 4/16 (25.0%); possible cure in 9/16 (53.2%) and inconclusive results in 3/16 (18.8%). The antibody and complement-mediated lysis reaction was in keeping with the xenodiagnosis in 18/22 cases, having shown negative results after treatment earlier than classical serological reactions. One aplastic anaemia patient receiving corticosteroid presented lymphoproliferative disease 6 years after being treated with benznidazol for acute Chagas' disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2124370     DOI: 10.1590/s0036-46651990000100004

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


  10 in total

Review 1.  Chagas disease.

Authors:  A R L Teixeira; N Nitz; M C Guimaro; C Gomes; C A Santos-Buch
Journal:  Postgrad Med J       Date:  2006-12       Impact factor: 2.401

2.  High resolution of Trypanosoma cruzi amastigote antigen in serodiagnosis of different clinical forms of Chagas' disease.

Authors:  T K Matsumoto; S Hoshino-Shimizu; P M Nakamura; H F Andrade; E S Umezawa
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

3.  Involvement of CD4(+) Th1 cells in systemic immunity protective against primary and secondary challenges with Trypanosoma cruzi.

Authors:  D F Hoft; A R Schnapp; C S Eickhoff; S T Roodman
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

4.  Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions.

Authors:  Ivo Santana Caldas; André Talvani; Sérgio Caldas; Cláudia Martins Carneiro; Marta de Lana; Paulo Marcos da Matta Guedes; Maria Terezinha Bahia
Journal:  Parasitol Res       Date:  2008-05-04       Impact factor: 2.289

Review 5.  Chagas' disease.

Authors:  H B Tanowitz; L V Kirchhoff; D Simon; S A Morris; L M Weiss; M Wittner
Journal:  Clin Microbiol Rev       Date:  1992-10       Impact factor: 26.132

Review 6.  Chagas disease and breast-feeding.

Authors:  Francesca F Norman; Rogelio López-Vélez
Journal:  Emerg Infect Dis       Date:  2013-10       Impact factor: 6.883

7.  The TcI and TcII Trypanosoma cruzi experimental infections induce distinct immune responses and cardiac fibrosis in dogs.

Authors:  Ana Luiza Cassin Duz; Paula Melo de Abreu Vieira; Bruno Mendes Roatt; Rodrigo Dian Oliveira Aguiar-Soares; Jamille Mirelle de Oliveira Cardoso; Flávia Carvalho Bitencourt de Oliveira; Levi Eduardo Soares Reis; Washington Luiz Tafuri; Vanja Maria Veloso; Alexandre Barbosa Reis; Cláudia Martins Carneiro
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-12       Impact factor: 2.743

8.  Oral Route Driven Acute Trypanosoma cruzi Infection Unravels an IL-6 Dependent Hemostatic Derangement.

Authors:  Dina Antunes; Alessandro Marins-Dos-Santos; Mariana Tavares Ramos; Barbara Angelica S Mascarenhas; Carlos José de Carvalho Moreira; Désio Aurélio Farias-de-Oliveira; Wilson Savino; Robson Q Monteiro; Juliana de Meis
Journal:  Front Immunol       Date:  2019-05-14       Impact factor: 7.561

9.  Opportunity cost for early treatment of Chagas disease in Mexico.

Authors:  Janine M Ramsey; Miguel Elizondo-Cano; Gilberto Sanchez-González; Adriana Peña-Nieves; Alejandro Figueroa-Lara
Journal:  PLoS Negl Trop Dis       Date:  2014-04-17

10.  Evolution of anti-Trypanosoma cruzi antibody production in patients with chronic Chagas disease: Correlation between antibody titers and development of cardiac disease severity.

Authors:  Ingebourg Georg; Alejandro Marcel Hasslocher-Moreno; Sergio Salles Xavier; Marcelo Teixeira de Holanda; Eric Henrique Roma; Maria da Gloria Bonecini-Almeida
Journal:  PLoS Negl Trop Dis       Date:  2017-07-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.